Kalaris reports positive TH103 Phase 1a data in neovascular AMD

July 17, 2026 7:00 AM

Kalaris Therapeutics (Nasdaq: KLRS) reported positive data from expanded cohorts in its Phase 1a single ascending dose trial of TH103 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found